Novartis Ag

Morphosys Ag

Novartis Pharma Ag

Julia Neugebauer

Stefanie Urlinger

Christoph Heusser

Eveline Schaadt

Maximilian Woisetschlaeger

Steffen Runz

John Trauger

Marta Cosenza

Jennifer Brogdon

Kurt Alex Heldwein

William Dole

Yuting Tang

Annika Schmid

Thomas Tiller

Tanja Herrmann

Andreas Bültmann

Andrei Igorevich Voznesensky

Kerstin Uhland

Winfried Elis

Barbara Bachler-Konetzki

Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Anti-BAFFR antibody formulations and methods of use thereof

The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer.

Antibodies specific for human complement C5A receptor (C5AR)

The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.

Antibodies targeting Glycoprotein VI

The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.

Humanized antibodies for CD3

The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region. The modified constant region prevents the recognition of the Fab molecules by anti-Fab antibodies present in a host's serum. The disclosure further relates to methods of generating such modified Fab molecules for biological, diagnostic, pharmaceutical and other uses.

Fab molecules with a rodent hinge region and a non-rodent CH1 region

The present invention relates to monoclonal antibodies binding to human angiopoetin-like protein 4 (hereinafter, sometimes referred to as 'ANGPTL4'), and pharmaceutical compositions and methods of treatment comprising the same.

Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use

The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as 'LOX-1'), and pharmaceutical compositions and methods of treatment comprising the same.

Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies

Lectin-like oxidized LDL receptor 1 antibodies and methods of use

Anti-BAFFR antibody formulations

The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.

Compositions and methods of use for therapeutic antibodies

Growing community of inventors

Munich, Germany

Julia Neugebauer